BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 26, 2004
 |  BioCentury  |  Tools & Techniques

Mass Listeria

When MedImmune Inc. licensed rights to EphA2 from Purdue University in 2001, the company's first order of business was to develop antibodies against the cancer target. More recently, the company decided to add a complementary approach by developing EphA2 cancer vaccines, and set about looking for a platform with which to deliver the antigen. Last week, MEDI placed its bet with Cerus Corp.'s Listeria technology, which the partners hope will provide a broad immune response and straightforward manufacturing.

EphA2 is a receptor tyrosine kinase that, when overexpressed, promotes tumor growth and metastasis. According to MEDI (Gaithersburg, Md.), the target...

Read the full 491 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >